Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Active-control, Phase 2/3 Study of First-line Intratumoral CMP-001 in Combination With Intravenous Nivolumab Compared to Nivolumab Monotherapy in Subjects With Unresectable or Metastatic Melanoma

NCT04695977 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT04695977
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04695977 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Active-control, Phase 2/3 Study of First-line Intratumoral CMP-001 in Combination With Intravenous Nivolumab Compared to Nivolumab Monotherapy in Subjects With Unresectable or Metastatic Melanoma
Lead sponsor
Regeneron Pharmaceuticals
Phase
Phase 2/3
Overall status
Terminated
Start date
February 24, 2021
Completion date
July 22, 2024
Enrollment
20 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma, melanoma, metastatic melanoma, unresectable melanoma